Vitamin D receptor agonists to treat diseases involving CXCL12 activity
US9895381B2 · kind B2 · utility
2Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2015 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | Dec 4, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/496
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.